Press release – No. 1 / 2026 Zealand Pharma to present at the J.P. Morgan Healthcare Conference Copenhagen, Denmark, January 5, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that the Company will participate in the 44th J.P. Morgan Healthcare Conference on January 12-15, 2026 in San Francisco, California. Adam Steensberg, President and Chief Executive Officer, will take par ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of BioRay Biopharmaceutical Co., Ltd. 浙 江 博 銳 生 物 製 藥 股 份 有 限 公 司 (the "Company") (A joint stock company incorporated ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. BioRay Biopharmaceutical Co., Ltd. 浙 江 博 銳 生 物 製 藥 股 份 有 限 公 司 (a joint stock company incorporated in the People's Republic of China with limited ...

NEW YORK, Jan. 5, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Citius Oncology, Inc. (NASDAQ: CTOR) on behalf of the company's shareholders.  The investigation seeks to determine whether Citius Oncology's directors breached their fiduciary duties in connection with recent corporate actions. If you are a shareholder of Citius Oncology and are interested in obtaining additional information about your rights and options, please visit us at: https://pjlfirm.com/citius-oncolog ...

NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced a significant scientific and manufacturing achievement. Through its investment in PsyLabs, Psyence BioMed has become the first Nasdaq-listed company to produce GMP-compliant, high-purity ibogaine hydrochloride (Ibogaine HCl) derived from a naturally extracted ...

Interim safety and efficacy data to be reported in Q1 VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today reported that it completed the enrollment and dosing of the 20 patients required for the planned formal interim analysis in its ongoing Phase 2 clinical study evaluating NGC-Cap, Processa’s proprietary combination treatment of PCS6422 and capecitabine, in pat ...

公司近期动态 - 公司总裁兼首席执行官Chris Cargill将于2026年1月13日太平洋标准时间下午1:30在第43届摩根大通医疗健康年会上发表演讲 [1] - 投资者、分析师及公众可通过网络直播链接收听演讲实况 [1] - 演示文稿将在公司网站的投资者关系板块发布 [2] 公司业务定位与战略 - 公司是一家技术驱动的生物制药公司 致力于为日本及全球未满足需求的患者研发新的专科药物 [2] - 公司在日本建立了敏捷的新一代商业化业务 以开发和商业化创新药物 包括多款已上市产品 旨在服务日本这一高价值、庞大且增长的市场以及更广泛的亚太地区市场 [3] 研发管线与平台 - 公司依托其独特的NxWave™发现平台 正在推进一个包含超过30个活跃项目的广泛研发管线 涵盖从早期发现到后期临床阶段 [4] - 该管线由内部开发及与领先药企和生物技术公司合作推进 [4] - 管线中的候选药物具有潜在同类首创或同类最佳潜力 专注于解决肥胖及代谢疾病、神经学/神经精神疾病以及免疫与炎症等一些增长最快的医疗领域内未满足的重大需求 [4] 公司基本情况 - 公司在日本东京和大阪、英国伦敦和剑桥、瑞士巴塞尔以及韩国首尔等关键地点拥有约400名员工 [5] - 公司在东京证券交易所上市 股票代码为4565 [5]

PHILADELPHIA, Jan. 5, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period"). Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than January 9, 2026, seek to be appointed as a lead ...

VANCOUVER, British Columbia and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at the 44th Annual J.P. Morgan Healthcare Conference, taking place in San Francisco, CA from January 12-15, 2026. Company Presentation Details: Date:Monday, January 12, 2026 T ...

公司核心人事变动 - Biodexa Pharmaceuticals PLC宣布立即晋升Fiona Sharp为首席财务官兼公司秘书并选举其进入董事会[2] - 原首席财务官兼公司秘书Stephen Stamp将卸任相关职务但保留首席执行官职位[4] 新任首席财务官背景 - Fiona Sharp自2019年12月加入公司担任集团财务总监期间已承担许多首席财务官职责[3] - 加入Biodexa前曾担任Hywel Dda大学健康委员会的财务助理总监该机构拥有超10,000名员工及约8亿英镑预算[3] - 更早于1999年至2018年初在Chime Communications Group担任职责不断增加的财务职位该公司营收约5.7亿英镑曾于英国上市[3] 公司业务与研发管线 - Biodexa是一家临床阶段生物制药公司专注于开发针对未满足医疗需求疾病的创新产品管线[2][5] - 主要研发项目包括eRapa用于治疗家族性腺瘤性息肉病和非肌层浸润性膀胱癌[5] - 主要研发项目包括tolimidone用于治疗1型糖尿病[5] - 主要研发项目包括MTX110正在研究用于治疗侵袭性罕见/孤儿脑癌适应症[5] 核心产品技术特点 - eRapa是雷帕霉素的口服胶囊制剂雷帕霉素是一种mTOR抑制剂在调节细胞代谢、生长和增殖的信号通路中起重要作用[6] - tolimidone是一种口服、强效、选择性的Lyn激酶抑制剂在糖尿病动物模型中通过胰岛素增敏作用展示血糖控制潜力[6] - MTX110是组蛋白去乙酰化酶抑制剂帕比司他的溶解配方可通过对流增强输送以化疗剂量直接递送至肿瘤部位绕过血脑屏障[7] - 公司拥有三项专有药物递送技术专注于改善药物的生物递送和生物分布[8]